More Radiopharm Theranostics Limited news
Radiopharm Theranostics LimitedASX: RAD

SPL: Research & Option Agreement with Radiopharm Theranostics

Sep 30, 2025 at 12:06 AM EDT · Issued by Radiopharm Theranostics Limited

Filed with ASX · Sep 30, 2025 at 12:06 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/splresearch-and-option-agreement-with-radiopharm-theranostics-1

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

  • Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)Sep 18, 2025
  • Appendix 4E and Preliminary Final ReportAug 29, 2025
  • Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business UpdateJul 29, 2025
  • Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)Jul 28, 2025
  • RAD receives IND approval from US FDA for Betabart (RV-01)Jul 27, 2025

Later from Radiopharm Theranostics

  • Radiopharm received approval for RAD 202 trial accelerationSep 30, 2025
  • Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical TrialOct 1, 2025
  • Trading HaltOct 15, 2025
  • RAD completes A$35 M Placement and launches A$5 M SPPOct 19, 2025
  • ProspectusOct 20, 2025
All Radiopharm Theranostics news releases↗

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer